Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

20191,003 citationsJournal Articlebronze Open Access

Authors

Seock‐Ah Im · Seoul National University Hospital

Yen‐Shen Lu · National Taiwan University Hospital

Aditya Bardia · Harvard University

Nadia Harbeck · Ludwig-Maximilians-Universität München

Marco Colleoni · European Institute of Oncology

Fábio Franke · Hospital Universitário Cajuru

Louis W.C. Chow

Abstract

This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 4, pp. 307-316

DOI: 10.1056/nejmoa1903765

Field-Weighted Citation Impact: 99.43